2.13Open2.13Pre Close0 Volume65 Open Interest2.50Strike Price0.00Turnover1258.27%IV10.19%PremiumJan 17, 2025Expiry Date2.09Intrinsic Value100Multiplier6DDays to Expiry0.04Extrinsic Value100Contract SizeAmericanOptions Type-0.6200Delta0.5725Gamma0.19Leverage Ratio-0.0211Theta-0.0003Rho-0.12Eff Leverage0.0002Vega
Relmada Therapeutics Stock Discussion
Dow Jones· 5 mins ago
Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017
Relmada Therapeutics has Commenced a Process to Explore Strategic Alternatives to Maximize Shareholder Value
Relmada Therapeutics Reports That Data Monitoring Committee (DMC) Assessment Indicates That the Phase 3 Reliance II Trial Is Futile at Its Interim Analysis and Is Unlikely to Meet the Primary Efficacy Endpoint With Statistical Significance
No comment yet